Immunosuppressive Treatment in Multiple Sclerosis

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Biomarker efficacy in multiple sclerosis diagnosis and treatment

The goal in studies concerning biomarkers in autoimmune diseases is finding a marker which fluctuates in correlation with the disease’s severity and settles within normal borders after effective treatment. This marker would later be used as an efficient tool in diagnosis and analysis of medicine clout. It seems the most cogent biomarkers are those measurable in serum or plasma. MS is a neurolog...

متن کامل

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

BACKGROUND In progressive multiple sclerosis (PMS), disease-modifying therapies have not been shown to reduce disability progression. OBJECTIVE The impact from immunosuppressive therapy in PMS was explored by analyzing cerebrospinal fluid (CSF) biomarkers of axonal damage (neurofilament light protein, NFL), astrogliosis (glial fibrillary acidic protein, GFAP), and B-cell regulation (CXCL13). ...

متن کامل

Multiple Sclerosis in Iran

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS). This highlydisabling disorder is characterized by a variable clinical course. MS is a heterogeneous disease with acomplex pathology and significant social and economic impact. MS is associated with dysfunction ofparts of the nervous system which results in a range of signs and symptoms, ...

متن کامل

[Natalizumab treatment in multiple sclerosis].

Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting clinical course. Some disease modifying medications for preventing the relapses including natalizumab (NTZ) are approved in Japan. Natalizumab (NTZ), a monoclonal antibody against α4 integrin present on the surface of lymphocytes, inhibits the bind...

متن کامل

Fingolimod treatment in multiple sclerosis

Objective: To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume. Methods: In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry

سال: 1978

ISSN: 0022-3050

DOI: 10.1136/jnnp.41.9.862-b